Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) Director Edgar Engleman sold 31,257 shares of the business’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $0.92, for a total transaction of $28,756.44. Following the transaction, the director now owns 269,823 shares in the company, valued at approximately $248,237.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Edgar Engleman also recently made the following trade(s):
- On Thursday, November 16th, Edgar Engleman sold 8,571 shares of Bolt Biotherapeutics stock. The stock was sold at an average price of $0.96, for a total transaction of $8,228.16.
Bolt Biotherapeutics Price Performance
NASDAQ BOLT traded down $0.03 on Monday, reaching $0.91. The company’s stock had a trading volume of 184,152 shares, compared to its average volume of 165,264. The firm has a market cap of $34.73 million, a PE ratio of -0.48 and a beta of 0.83. The business has a 50-day moving average price of $1.01 and a 200 day moving average price of $1.28. Bolt Biotherapeutics, Inc. has a 52 week low of $0.86 and a 52 week high of $2.03. The company has a current ratio of 6.69, a quick ratio of 7.42 and a debt-to-equity ratio of 0.14.
Analysts Set New Price Targets
Hedge Funds Weigh In On Bolt Biotherapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in BOLT. Bank of New York Mellon Corp boosted its position in Bolt Biotherapeutics by 13.0% in the first quarter. Bank of New York Mellon Corp now owns 91,293 shares of the company’s stock valued at $249,000 after buying an additional 10,475 shares in the last quarter. Renaissance Technologies LLC boosted its position in Bolt Biotherapeutics by 226.3% in the first quarter. Renaissance Technologies LLC now owns 290,100 shares of the company’s stock valued at $795,000 after buying an additional 201,200 shares in the last quarter. PDT Partners LLC acquired a new position in Bolt Biotherapeutics in the first quarter valued at about $33,000. Millennium Management LLC acquired a new position in Bolt Biotherapeutics in the second quarter valued at about $391,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Bolt Biotherapeutics in the second quarter valued at about $30,000. 73.56% of the stock is currently owned by institutional investors and hedge funds.
Bolt Biotherapeutics Company Profile
Bolt Biotherapeutics, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.
- Five stocks we like better than Bolt Biotherapeutics
- What is the Hang Seng index?
- The most upgraded stocks in November have two things in common
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Monday.com rocked earnings like it’s the weekend
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Plan to own one retailer? Make it this one
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.